Nanobiotix reports 41.7% response rate in Phase 1 trial of NBTXR3 combination in anti-PD-1-resistant melanoma

• Nanobiotix reported preliminary antitumor activity with JNJ-1900 (NBTXR3) in a Phase 1 trial involving 24 heavily pretreated patients with anti-PD-1-resistant advanced cutaneous melanoma.
• Treatment combined a single tumor injection, radiotherapy and subsequent immune checkpoint therapy; responses occurred in both injected and non-injected lesions.
• The regimen showed an acceptable safety profile, with no new safety signals observed.
• Results were presented at the European Society for Medical Oncology meeting in Madrid on October 24, 2026.
• The preliminary findings from the single-arm study support further evaluation in larger randomized trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanobiotix SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610240700OMX_____CNEWS_EN_GNW9852435_en) on October 24, 2026, and is solely responsible for the information contained therein.